StockData
Regen BioPharma Inc logo

Regen BioPharma Inc (RGBP) stock

RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026Score 2/30
$0.00+0.00 (+50.00%)

Close on Oct 19, 2026Market cap $92.33KP/E –Yield –

Regen BioPharma r&d expenses

Research and development expenses are spending on new products and technology.

Regen BioPharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $223.94K, up 568.0% year over year. For fiscal 2025 it was $11.73K, down 92.4% from the year before. Over ten years it grew -27.2% a year on average. The highest annual figure on record is $1.15M in fiscal 2017.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$11.73K-92.4%
FY2024Sep 30, 2024$153.69K-27.6%
FY2023Sep 30, 2023$212.30K+34.2%
FY2022Sep 30, 2022$158.14K+330.8%
FY2021Sep 30, 2021$36.70K+176.3%
FY2020Sep 30, 2020$13.29K-70.9%
FY2019Sep 30, 2019$45.61K-87.8%
FY2018Sep 30, 2018$374.44K-67.4%
FY2017Sep 30, 2017$1.15M+71.3%
FY2016Sep 30, 2016$671.10K+137.7%
FY2015Sep 30, 2015$282.30K+1082.8%
FY2014Sep 30, 2014$23.87K+184.3%
FY2013Sep 30, 2013$8.39K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$0–
Q2 FY2026CQ1 2026Mar 31, 2026$2.22K–
Q1 FY2026CQ4 2025Dec 31, 2025$210.00K–
Q4 FY2025CQ3 2025Sep 30, 2025$11.73K-65.0%
Q3 FY2025CQ2 2025Jun 30, 2025$0-100.0%
Q2 FY2025CQ1 2025Mar 31, 2025$0-100.0%
Q1 FY2025CQ4 2024Dec 31, 2024$0-100.0%
Q4 FY2024CQ3 2024Sep 30, 2024$33.52K-5.1%
Q3 FY2024CQ2 2024Jun 30, 2024$32.50K-27.8%
Q2 FY2024CQ1 2024Mar 31, 2024$40.13K+10.1%
Q1 FY2024CQ4 2023Dec 31, 2023$47.53K-50.2%
Q4 FY2023CQ3 2023Sep 30, 2023$35.34K-45.0%
Q3 FY2023CQ2 2023Jun 30, 2023$45.00K+44.9%
Q2 FY2023CQ1 2023Mar 31, 2023$36.45K+33.1%
Q1 FY2023CQ4 2022Dec 31, 2022$95.51K+169.7%
Q4 FY2022CQ3 2022Sep 30, 2022$64.27K+208.8%
Q3 FY2022CQ2 2022Jun 30, 2022$31.06K+117.9%
Q2 FY2022CQ1 2022Mar 31, 2022$27.39K+5249.6%
Q1 FY2022CQ4 2021Dec 31, 2021$35.42K+3042.7%
Q4 FY2021CQ3 2021Sep 30, 2021$20.81K+609.8%
Q3 FY2021CQ2 2021Jun 30, 2021$14.25K+118683.3%
Q2 FY2021CQ1 2021Mar 31, 2021$512-81.9%
Q1 FY2021CQ4 2020Dec 31, 2020$1.13K-85.0%
Q4 FY2020CQ3 2020Sep 30, 2020$2.93K-86.9%
Q3 FY2020CQ2 2020Jun 30, 2020$12-99.9%
Q2 FY2020CQ1 2020Mar 31, 2020$2.82K+109.7%
Q1 FY2020CQ4 2019Dec 31, 2019$7.52K+14.0%
Q4 FY2019CQ3 2019Sep 30, 2019$22.34K-34.4%
Q3 FY2019CQ2 2019Jun 30, 2019$15.33K+48.0%
Q2 FY2019CQ1 2019Mar 31, 2019$1.35K-98.1%
Q1 FY2019CQ4 2018Dec 31, 2018$6.59K-98.8%
Q4 FY2018CQ3 2018Sep 30, 2018$34.05K-92.6%
Q3 FY2018CQ2 2018Jun 30, 2018$10.36K-97.2%
Q2 FY2018CQ1 2018Mar 31, 2018$71.95K-74.7%
Q1 FY2018CQ4 2017Dec 31, 2017$548.09K+1183.8%
Q4 FY2017CQ3 2017Sep 30, 2017$462.82K+149.6%
Q3 FY2017CQ2 2017Jun 30, 2017$374.45K–
Q2 FY2017CQ1 2017Mar 31, 2017$284.69K–
Q1 FY2017CQ4 2016Dec 31, 2016$42.69K–
Q4 FY2016CQ3 2016Sep 30, 2016$185.39K–

More Regen BioPharma figures

See a number that looks wrong?